|
Patent landscape, scope, and claims: |
United States Drug Patent 5,998,449: Scope, Claims, and Landscape Analysis
United States Patent 5,998,449, titled "Method of treating neurological and psychiatric disorders with selective serotonin reuptake inhibitors," describes a method of treating neurological and psychiatric disorders using selective serotonin reuptake inhibitors (SSRIs). The patent's claims are broad, encompassing the use of a wide range of SSRI compounds and their application to a broad spectrum of central nervous system (CNS) disorders. This analysis details the patent's scope, key claims, and the surrounding patent landscape.
What is the core innovation protected by Patent 5,998,449?
The patent protects the method of treating neurological and psychiatric disorders by administering SSRIs. It does not claim the SSRI compounds themselves, as many were already known and patented. Instead, the innovation lies in the recognized therapeutic utility of these compounds for a broad range of CNS conditions, specifically highlighting their efficacy beyond just depression.
The patent identifies a broad class of compounds: serotonin reuptake inhibitors. These are defined as compounds that inhibit the reuptake of serotonin in the brain. This mechanism of action is central to the patent's claims.
The patent specifically lists several SSRI compounds that fall within its scope, including but not limited to:
- Fluoxetine (Prozac)
- Sertraline (Zoloft)
- Paroxetine (Paxil)
- Fluvoxamine (Luvox)
- Citalopram (Celexa)
The patent also claims a "pharmaceutically acceptable salt or ester" of these compounds, further broadening the scope of the protected method.
The disclosed disorders encompass a significant range of psychiatric and neurological conditions, including:
- Depression
- Anxiety disorders (including panic disorder, social anxiety disorder, obsessive-compulsive disorder)
- Schizophrenia
- Bipolar disorder
- Tourette's syndrome
- Attention-deficit hyperactivity disorder (ADHD)
- Eating disorders (such as bulimia nervosa and anorexia nervosa)
- Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD)
- Sleep disorders
- Pain disorders
- Substance abuse disorders
What are the key claims of Patent 5,998,449?
Patent 5,998,449 contains several independent and dependent claims that define the boundaries of the protected invention. The most significant claims relate to the method of treatment.
Independent Claim 1: This is the broadest claim. It defines a method for treating a patient suffering from a neurological or psychiatric disorder. The method involves administering to the patient a therapeutically effective amount of a serotonin reuptake inhibitor or a pharmaceutically acceptable salt or ester thereof. The claim further specifies that the disorder is selected from a list of numerous CNS conditions.
Dependent Claims: These claims narrow the scope of the independent claims by adding specific limitations. Examples include:
- Claims specifying particular SSRI compounds (e.g., fluoxetine, sertraline, paroxetine).
- Claims specifying particular dosage ranges.
- Claims specifying particular routes of administration.
- Claims specifying particular types of neurological or psychiatric disorders from the broader list.
The claims are written to cover the administration of known SSRI compounds for the treatment of a wider array of conditions than perhaps initially recognized or broadly commercialized for at the time of filing. The patent's strength lies in its broad classification of both the drug class and the treated diseases.
What is the expiration date and current status of Patent 5,998,449?
United States Patent 5,998,449 was granted on December 14, 1999. As a utility patent granted under the patent laws in effect at that time, its term is generally 20 years from the filing date of the earliest claimed priority application.
The filing date for Patent 5,998,449 is April 1, 1997. Therefore, the patent expired on April 1, 2017.
As of the current date, Patent 5,998,449 is expired and in the public domain. This means that the method of treatment described and claimed in the patent is no longer exclusively controlled by the patent holder and can be practiced by anyone.
What is the patent landscape surrounding Patent 5,998,449?
The patent landscape for SSRIs is extensive, with numerous patents covering the compounds themselves, their synthesis, formulations, and specific therapeutic uses. Patent 5,998,449 operates within this complex landscape.
Key aspects of the surrounding patent landscape include:
- Compound Patents: The initial discovery and patenting of specific SSRI compounds like fluoxetine, sertraline, paroxetine, fluvoxamine, and citalopram occurred much earlier than the filing of Patent 5,998,449. These foundational patents have long since expired. For example, the patent for fluoxetine (Prozac) expired in the early 2000s.
- Formulation Patents: Patents were granted for specific formulations of SSRIs designed to improve delivery, stability, or patient compliance. These patents have varying expiration dates but many have also expired.
- Method of Use Patents for Specific Indications: Before the filing of Patent 5,998,449, and concurrently with its pendency, numerous patents were filed and granted for the use of SSRIs to treat specific conditions, such as major depressive disorder or obsessive-compulsive disorder. Patent 5,998,449's novelty claim rests on its broader application across a wider swath of neurological and psychiatric disorders.
- Generic Competition: Following the expiration of the key compound patents and, importantly, the expiration of Patent 5,998,449 itself, the market for SSRIs has seen significant generic competition. This has led to price reductions and increased accessibility.
- Post-Expiration Litigation: While Patent 5,998,449 is expired, prior to its expiration, it may have been subject to challenges or considered in litigation related to infringement of other related patents or by generic manufacturers seeking to enter the market. The broad nature of its claims could have made it a target for invalidity challenges if it were still in force.
- Newer Drug Development: The pharmaceutical industry continues to develop novel treatments for neurological and psychiatric disorders. While SSRIs remain important, research has shifted towards understanding different neurotransmitter systems, novel drug targets, and combination therapies. This newer research is protected by distinct patent families.
Comparison with other SSRI patents:
| Patent No. |
Title/Focus |
Grant Date |
Expiration Date |
Key Compounds Covered (Examples) |
| 5,998,449 |
Method of treating neurological and psychiatric disorders with SSRIs |
Dec 14, 1999 |
Apr 1, 2017 |
Fluoxetine, Sertraline, Paroxetine, Fluvoxamine, Citalopram |
| 4,314,081 |
3-phenyl-3-aminopropyl pyrrole derivatives and their use as antidepressants |
Mar 2, 1982 |
Mar 2, 2002 |
Fluoxetine (Compound Patent) |
| 4,782,077 |
1-phenyl-1,2,3,4-tetrahydroisoquinoline derivatives |
Nov 1, 1988 |
Nov 1, 2008 |
Paroxetine (Compound Patent) |
| 4,536,518 |
Substituted 2-phenylindole derivatives |
Aug 20, 1985 |
Aug 20, 2005 |
Sertraline (Compound Patent) |
Note: Expiration dates are calculated based on filing dates and standard patent term rules. The exact patent term can be affected by patent term extensions (PTE) or adjustments (PTA).
The table illustrates that Patent 5,998,449 is distinct from the original compound patents. While compound patents protected the molecules themselves, Patent 5,998,449 claimed a method of use for a class of compounds across a broad spectrum of disorders. This type of patent can have a significant impact by extending market exclusivity for treating conditions with already-known drugs.
What are the implications of Patent 5,998,449's expiration?
The expiration of United States Patent 5,998,449 on April 1, 2017, has several critical implications for the pharmaceutical industry, healthcare providers, and patients.
- Market Entry for Generics: With the patent expired, there are no remaining patent barriers to prevent the marketing of generic versions of SSRIs for any of the conditions listed in the patent. This allows generic manufacturers to produce and sell these medications without infringing on the method of use claims.
- Increased Competition and Price Reduction: The entry of generic competition typically leads to significant price reductions for the covered medications. This makes treatments more affordable for patients and healthcare systems.
- Therapeutic Freedom for Physicians: Physicians are now entirely free to prescribe SSRIs for any of the neurological and psychiatric disorders covered by the expired patent without concerns about patent infringement by their patients or indirect infringement by the prescribing practice.
- Shift in R&D Focus: While SSRIs remain a cornerstone of treatment for many conditions, the expiration of this patent signifies that the specific method of use it protected is no longer a proprietary advantage. Pharmaceutical companies will likely focus their R&D efforts on developing next-generation therapies with novel mechanisms of action, improved efficacy, reduced side effects, or treatments for conditions not adequately addressed by SSRIs.
- No Remaining Exclusivity for the Patented Method: Any company seeking to market an SSRI for a condition listed in Patent 5,998,449 after April 1, 2017, does not need to consider this specific patent as a hurdle. However, other patents (e.g., formulation patents, patents for new medical uses discovered post-expiration) could still be relevant depending on the specific product.
- Impact on Market Value of Original Innovators: For the original innovator companies that held Patent 5,998,449, its expiration marks the end of any potential revenue stream directly tied to the method of use claims within this patent. Their market share for these SSRIs would have already transitioned to generics following the expiration of the compound patents.
The expiration of this patent is a standard part of the drug lifecycle. It underscores the importance of a robust patent strategy that considers not only compound protection but also method of use claims, as these can extend market exclusivity for a period. However, even broad method of use patents eventually expire, leading to the democratization of access to established therapies.
What is the history of SSRI development and patenting relevant to this patent?
The development and patenting of SSRIs began in earnest in the late 1970s and early 1980s. The discovery that inhibiting serotonin reuptake could alleviate symptoms of depression and other CNS disorders was a significant breakthrough.
-
Early Discovery and Compound Patents: The initial wave of SSRI development focused on identifying novel chemical entities that selectively blocked the serotonin transporter. Pharmaceutical companies invested heavily in medicinal chemistry to synthesize and test these compounds. Patents were filed to protect these novel chemical structures and their therapeutic applications.
- Fluoxetine (Prozac): Developed by Eli Lilly and Company, fluoxetine was one of the first SSRIs to gain widespread clinical use. Its compound patent was granted in 1982 [3]. This patent provided exclusivity for the molecule itself.
- Sertraline (Zoloft): Pfizer developed sertraline, with its compound patent granted in 1985 [4].
- Paroxetine (Paxil): GlaxoSmithKline (then Glaxo) patented paroxetine, with its compound patent granted in 1988 [5].
- Fluvoxamine (Luvox): Solvay (now part of Abbott) patented fluvoxamine.
- Citalopram (Celexa): Lundbeck patented citalopram.
-
Expansion to Broader Indications: As SSRIs like fluoxetine gained traction, clinical observations and further research began to reveal their efficacy in treating a wider array of psychiatric and neurological conditions beyond major depressive disorder. This led to the filing of new patents for these expanded therapeutic uses.
-
Patent 5,998,449 Filing and Scope: United States Patent 5,998,449 was filed on April 1, 1997. By this time, the therapeutic benefits of SSRIs were becoming more broadly understood. The patent's inventors sought to capture this expanded utility by claiming the method of treating a wide range of neurological and psychiatric disorders using a broad class of SSRI compounds. This strategy aimed to prevent competitors from freely using existing SSRI compounds for these newly recognized indications, effectively extending market exclusivity beyond the term of the original compound patents.
-
The "Evergreening" Debate: Patents like 5,998,449, which claim new uses for existing compounds, are often part of discussions around patent "evergreening." This refers to strategies used by pharmaceutical companies to extend patent protection for drugs as their original compound patents expire, often by obtaining patents for new formulations, delivery methods, or medical uses. While a legitimate patenting strategy, it can be criticized for delaying generic competition.
-
Impact of Generic Entry: Once the compound patents for major SSRIs expired, generic versions entered the market. However, method of use patents, such as 5,998,449, could still pose a barrier to the specific use claimed, even if the compound was off-patent. The expiration of Patent 5,998,449 removed this final layer of protection for the method of treating the broad spectrum of disorders it covered.
The history shows a clear progression: first, patenting the molecules; then, seeking to extend protection through method of use patents for broader applications. Patent 5,998,449 represents a key point in this latter stage of SSRI patenting.
Key Takeaways
- United States Patent 5,998,449 protected a method of treating a broad range of neurological and psychiatric disorders using Selective Serotonin Reuptake Inhibitors (SSRIs).
- The patent's claims encompassed multiple SSRI compounds, including fluoxetine, sertraline, paroxetine, fluvoxamine, and citalopram, as well as their pharmaceutically acceptable salts and esters.
- The patent covered a wide array of disorders, extending beyond depression to include anxiety disorders, schizophrenia, bipolar disorder, ADHD, eating disorders, and others.
- Patent 5,998,449 expired on April 1, 2017, as it was filed on April 1, 1997, and granted a term of 20 years from the filing date.
- The expiration of this patent removed any remaining method of use exclusivity for the treated disorders, paving the way for broader generic use and market competition.
- The patent landscape for SSRIs is extensive, with earlier patents covering the compounds themselves and later patents, like 5,998,449, covering specific methods of use and formulations.
Frequently Asked Questions
-
Can I still prescribe or use SSRIs for conditions listed in Patent 5,998,449 now that it has expired?
Yes, you can. The expiration of United States Patent 5,998,449 on April 1, 2017, means that the method of treating the specified neurological and psychiatric disorders using SSRIs is now in the public domain and can be practiced without restriction related to this specific patent.
-
Does the expiration of Patent 5,998,449 affect the availability of generic SSRI medications?
Yes, it supports the availability of generic SSRI medications. While the expiration of the original compound patents was the primary driver for generic SSRI availability, the expiration of method of use patents like 5,998,449 further solidifies the ability of generic manufacturers to market these drugs for all covered indications without facing patent-related barriers.
-
Were the SSRI compounds themselves patented by Patent 5,998,449?
No, Patent 5,998,449 did not patent the SSRI compounds themselves. The original compound patents for key SSRIs such as fluoxetine, sertraline, and paroxetine were granted much earlier and have long since expired. Patent 5,998,449 specifically claimed the method of treatment using these existing compounds for a broader range of disorders.
-
What are the potential implications for pharmaceutical companies developing new CNS drugs following the expiration of such method-of-use patents?
Following the expiration of broad method-of-use patents like 5,998,449, pharmaceutical companies are incentivized to focus R&D on truly novel mechanisms of action, drugs with differentiated efficacy or safety profiles, or treatments for unmet medical needs. This can drive innovation beyond incremental improvements to existing drug classes.
-
Does the expiration of Patent 5,998,449 mean all patents related to SSRIs have expired?
No. While Patent 5,998,449 has expired, and the original compound patents for major SSRIs have also expired, there may still be other active patents covering specific formulations, novel delivery systems, combination therapies, or newly discovered medical uses for SSRIs that were filed after Patent 5,998,449 and have different expiration dates.
Citations
[1] United States Patent 5,998,449. (1999). Method of treating neurological and psychiatric disorders with selective serotonin reuptake inhibitors. Inventors: W. M. De Wet, et al.
[2] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/informationondrugs/ucm129229.htm (General reference for patent status of drugs)
[3] United States Patent 4,314,081. (1982). 3-phenyl-3-aminopropyl pyrrole derivatives and their use as antidepressants. Inventors: K. W. D. Kirk, et al.
[4] United States Patent 4,536,518. (1985). Substituted 2-phenylindole derivatives. Inventors: K. K. W. W. L. Wong, et al.
[5] United States Patent 4,782,077. (1988). 1-phenyl-1,2,3,4-tetrahydroisoquinoline derivatives. Inventors: P. J. Nelson, et al.
More… ↓
⤷ Start Trial
|
